2,132 results match your criteria stool occult


[Application of fecal DNA methylation biomarkers detection in gastric cancer screening].

Zhonghua Yi Xue Za Zhi 2021 Mar;101(11):808-812

The First Affiliated Hospital of Soochow University,Suzhou 215006, China.

Explore the feasibility of fecal gene methylation for screening gastric cancer and its relationship with clinical characteristics of gastric cancer patients. One hundred and fifty-six stool samples of patients in general surgery or digestive department of the First Affiliated Hospital of Soochow University from August 2018 to December 2019 were collected, detailed clinical information of gastric cancer patients were recorded. All patients and normal controls were divided into two sets including train sets (=52)and test sets (=104). Read More

View Article and Full-Text PDF

Impact on healthcare resources of switch from fecal occult blood test to fecal immunochemical test within the English Bowel Cancer Screening Program: a single-center study.

Gastrointest Endosc 2021 Mar 13. Epub 2021 Mar 13.

The Royal Wolverhampton NHS Trust.

Background And Aims: In July 2019, fecal immunochemistry testing (FIT) replaced fecal occult blood test (FOBt) in England as the Bowel Cancer Screening Program (BCSP) screening tool. We aimed to assess the impact of this on healthcare resources at our BCSP center.

Methods: Two 6-month periods were initially analyzed for stool sample return and positivity rates. Read More

View Article and Full-Text PDF

Clinical Performance Evaluation of Feces Analyzer KU-F10.

Clin Lab 2021 Feb;67(2)

Background: Systematic performance verification is required before a laboratory can introduce a new measure-ment procedure for reporting results of patient testing. The aim of this study was to explore the basic performance and clinical application value of KU-F10 Feces analyzer.

Methods: We collected 530 fecal specimens in our hospital from October 2019 to February 2020, using manual methods as the gold standard. Read More

View Article and Full-Text PDF
February 2021

[Colorectal carcinoma - How can we improve prevention?]

Ther Umsch 2021 ;78(2):61-72

GastroZentrum Netzer AG, Lindenhofspital, Bern.

Colorectal carcinoma - How can we improve prevention? Colorectal cancer (CRC) is the second leading cause of cancer-related death in Europe. Comprehensive screening is useful and cost-effective. However, participation in screening programs in Switzerland is low and falls below 20 %. Read More

View Article and Full-Text PDF
February 2021

The colorectal cancer-associated faecal microbiome of developing countries resembles that of developed countries.

Genome Med 2021 Feb 16;13(1):27. Epub 2021 Feb 16.

Pathology & Data Analytics, Leeds Institute of Medical Research at St James's University Hospital, University of Leeds, Level 4 Wellcome Trust Brenner Building, Leeds, LS9 7TF, UK.

Background: The incidence of colorectal cancer (CRC) is increasing in developing countries, yet limited research on the CRC- associated microbiota has been conducted in these areas, in part due to scarce resources, facilities, and the difficulty of fresh or frozen stool storage/transport. Here, we aimed (1) to establish a broad representation of diverse developing countries (Argentina, Chile, India, and Vietnam); (2) to validate a 'resource-light' sample-collection protocol translatable in these settings using guaiac faecal occult blood test (gFOBT) cards stored and, importantly, shipped internationally at room temperature; (3) to perform initial profiling of the collective CRC-associated microbiome of these developing countries; and (4) to compare this quantitatively with established CRC biomarkers from developed countries.

Methods: We assessed the effect of international storage and transport at room temperature by replicating gFOBT from five UK volunteers, storing two in the UK, and sending replicates to institutes in the four countries. Read More

View Article and Full-Text PDF
February 2021

Diarrhoea in adults with coronavirus disease-beyond incidence and mortality: a systematic review and meta-analysis.

Infect Dis (Lond) 2021 05 15;53(5):348-360. Epub 2021 Feb 15.

Department of Introduction to Internal Medicine, Gastroenterology and Hepatology, Sechenov University, Moscow, Russian Federation.

Aim: Diarrhoea is a relatively common manifestation of coronavirus disease (COVID-19), but there is no systematic review which comprehensively describes it beyond its incidence and impact on prognosis. This study aims to provide a detailed systematic review of diarrhoea in adults with COVID-19.

Methods: A PUBMED and Scopus search (until 7 September 2020) was performed. Read More

View Article and Full-Text PDF

Enema based therapy using liposomal formulation of low molecular weight heparin for treatment of active ulcerative colitis: New adjunct therapeutic opportunity.

Mater Sci Eng C Mater Biol Appl 2021 Feb 6;121:111851. Epub 2021 Jan 6.

Institute of Nano Science and Technology, Habitat Centre, Phase 10, Sector 64, Mohali, Punjab 160062, India. Electronic address:

Ulcerative colitis (UC) is an idiopathic bowel disease involving chronic inflammation and ulcers in colon and implicates severe epithelial damage with disruption in colon homeostasis. Presently existing treatments possess serious concerns like off target effects and adverse reactions, drug inactivation, poor absorption and other complications resulting in poor bioavailability. In context of high risk of thrombotic events in UC patients, heparin can offer appreciable benefits in UC management due to its remarkable anti-coagulating properties, its ability to intervene inflammatory pathways and acceleration of wound healing process. Read More

View Article and Full-Text PDF
February 2021

Fecal Immunochemical Tests Detect Screening Participants with Multiple Advanced Adenomas Better than T1 Colorectal Cancers.

Cancers (Basel) 2021 Feb 5;13(4). Epub 2021 Feb 5.

Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Im Neuenheimer Feld 460, D-69120 Heidelberg, Germany.

Background: Fecal immunochemical tests (FITs) are widely used for colorectal cancer (CRC) screening. The detection of early-stage cancer and advanced adenoma (AA), the most important premalignant lesion, is highly relevant to reducing CRC-related deaths. We aimed to assess sensitivity for the detection of CRC and AA stratified by tumor stage; number; size; histology of AA; and by location, age, sex, and body mass index (BMI). Read More

View Article and Full-Text PDF
February 2021

Assessment of fecal calprotectin and fecal occult blood as point-of-care markers for soil-transmitted helminth attributable intestinal morbidity in a case-control substudy conducted in Côte d'Ivoire, Lao PDR and Pemba Island, Tanzania.

EClinicalMedicine 2021 Feb 30;32:100724. Epub 2021 Jan 30.

Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Basel, Switzerland.

Background: Infections with soil-transmitted helminths (STHs) may result in chronic inflammatory disorders affecting the human host. The objective of this study was to evaluate Fecal Calprotectin (FC) and Fecal Occult Blood (FOB) in individuals infected and non-infected with STHs to identify potential intestinal morbidity markers.

Methods: Stool from participants diagnosed positive for and concomitant STH infections from three countries was used to perform FC and FOB point-of-care assays. Read More

View Article and Full-Text PDF
February 2021

Time to Colonoscopy After Abnormal Stool-Based Screening and Risk for Colorectal Cancer Incidence and Mortality.

Gastroenterology 2021 Feb 2. Epub 2021 Feb 2.

Division of Gastroenterology, Department of Medicine, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California; Vatche and Tamar Manoukian Division of Digestive Diseases and Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, California. Electronic address:

Background And Aims: The optimal time interval for diagnostic colonoscopy completion after an abnormal stool-based colorectal cancer (CRC) screening test is uncertain. We examined the association between time to colonoscopy and CRC outcomes among individuals who underwent diagnostic colonoscopy after abnormal stool-based screening.

Methods: We performed a retrospective cohort study of veterans age 50 to 75 years with an abnormal fecal occult blood test (FOBT) or fecal immunochemical test (FIT) between 1999 and 2010. Read More

View Article and Full-Text PDF
February 2021

Laparoscopic removal of mesh migrating into the sigmoid colon after totally extraperitoneal (TEP) laparoscopic inguinal hernia repair with positive faecal occult blood test.

BMJ Case Rep 2021 Feb 4;14(2). Epub 2021 Feb 4.

Seoul National University Cancer Research Institute, Seoul, Korea (the Republic of).

A 76-year-old man was referred to our clinic after a foreign body seen in his sigmoid colon during a colonoscopy. He had undergone three operations for a left inguinal hernia within the previous 8 years, and the first procedure was a laparoscopic totally extraperitoneal approach. Four years later, removal of migrated and infected mesh was conducted by open approach. Read More

View Article and Full-Text PDF
February 2021

Barriers to Follow-Up Colonoscopy After Positive FIT or Multitarget Stool DNA Testing.

J Am Board Fam Med 2021 Jan-Feb;34(1):61-69

From the Division of Gastroenterology, University Hospitals Cleveland Medical Center, Cleveland OH (GSC, AG); Center for Community Health Integration and Department of Family Medicine, Case Western Reserve University, Cleveland OH (JW, KCS); Department of Population and Quantitative Health, Case Western Reserve University, Cleveland OH (SC, PF); and the Case Comprehensive Cancer Center, Cleveland OH (GSC, JW, PF, KCS).

Background: Fecal immunochemical testing (FIT) and multi-target stool DNA testing (mt-sDNA) are recommended colorectal cancer screening options but require follow-up with colonoscopy to determine the source of a positive result. We performed a retrospective analysis in an academic health system to determine adherence to colonoscopy in these patients.

Methods: We identified all patients aged 40 years and older with at least 1 primary care visit who had a positive FIT or mt-sDNA between January 2016 and June 2018. Read More

View Article and Full-Text PDF

Quantitative detection of SRY-Box 21 () gene promoter methylation as a stool-based noninvasive biomarker for early diagnosis of colorectal cancer by MethyLight method.

Indian J Cancer 2021 Jan 6. Epub 2021 Jan 6.

Department of Clinical Biochemistry, Kermanshah University of Medical Sciences, Kermanshah, Iran.

Background: In recent years, the study of potential epigenetic biomarkers in feces has been an attractive research approach for the noninvasive diagnosis of colorectal cancer (CRC). The aim of this study was to evaluate the stool-based DNA methylation potential of SRY-Box 21 (SOX21) gene promoter as an appropriate candidate biomarker for differentiating CRC patients and healthy individuals for the first time.

Methods: The MethyLight method was performed to analyze the methylation status of SOX21 gene promoter in fecal samples from 40 patients with CRC and 40 healthy controls. Read More

View Article and Full-Text PDF
January 2021

Stool DNA test targeting methylated syndecan-2 (SDC2) as a noninvasive screening method for colorectal cancer.

Biosci Rep 2021 Jan;41(1)

Division of Colorectal Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.

Despite the steadily increasing worldwide incidence of colorectal cancer (CRC), an effective noninvasive approach for early detection of CRC is still under investigation. The guaiac-based fecal occult blood test (FOBT) and fecal immunochemical test (FIT) have gained popularity as noninvasive CRC screening tests owing to their convenience and relatively low costs. However, the FOBT and FIT have limited sensitivity and specificity. Read More

View Article and Full-Text PDF
January 2021

A New Method for the Detection of Colorectal Cancer and the Precancerous Lesions: Occult Blood Testing Combination with Promoter Methylation in the Fecal Sample.

J Cancer 2021 1;12(2):335-342. Epub 2021 Jan 1.

Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.

Noninvasive stool-based DNA methylation testing emerges as a new approach for detecting colorectal cancer (CRC). However, its feasibility for early detection of CRC and precancerous lesions in the Chinese population remains inconclusive. In this study, we establish a possibilities screening method (sDNA-FOBT) for detecting CRC and precancerous lesions (hyperplastic polyps [HP] and adenomas [AD]) and evaluate its detection performance in the Chinese population. Read More

View Article and Full-Text PDF
January 2021

[Diagnostic performance of quantitative fecal immunochemical test in detection of advanced colorectal neoplasia].

Zhonghua Liu Xing Bing Xue Za Zhi 2020 Dec;41(12):2104-2111

Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.

To evaluate the diagnostic performance of quantitative fecal immunochemical testing (FIT) and to provide reference for designing effective colorectal cancer (CRC) screening strategy in China. Based on an ongoing randomized controlled trial comparing the colorectal cancer screening strategies, this current study involved 3 407 participants aged 50-74 years who had undergone colonoscopies. All the feces samples were collected from the participants prior to receiving the colonoscopy. Read More

View Article and Full-Text PDF
December 2020

Estimating the impact of differential adherence on the comparative effectiveness of stool-based colorectal cancer screening using the CRC-AIM microsimulation model.

PLoS One 2020 29;15(12):e0244431. Epub 2020 Dec 29.

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, United States of America.

Background: Real-world adherence to colorectal cancer (CRC) screening strategies is imperfect. The CRC-AIM microsimulation model was used to estimate the impact of imperfect adherence on the relative benefits and burdens of guideline-endorsed, stool-based screening strategies.

Methods: Predicted outcomes of multi-target stool DNA (mt-sDNA), fecal immunochemical tests (FIT), and high-sensitivity guaiac-based fecal occult blood tests (HSgFOBT) were simulated for 40-year-olds free of diagnosed CRC. Read More

View Article and Full-Text PDF

Occult Blood in Feces Is Associated With an Increased Risk of Ischemic Stroke and Myocardial Infarction: A Nationwide Population Study.

J Am Heart Assoc 2021 Jan 29;10(1):e017783. Epub 2020 Dec 29.

Department of Internal Medicine Liver Research InstituteSeoul National University College of Medicine Seoul Republic of Korea.

Background Although occult hemoglobin in feces is universally valued as a screening tool for colorectal cancer (CRC), only few studies investigated the clinical meaning of fecal immunochemical test (FIT) in other diseases. We evaluated the clinical utility of FIT in patients with cardiovascular diseases (namely, ischemic stroke and myocardial infarction [MI]). Methods and Results Using the National Health Insurance database, participants (aged >50 years) with CRC screening records from 2009 to 2012 were screened and followed up. Read More

View Article and Full-Text PDF
January 2021

Enteric-coated gelatin nanoparticles mediated oral delivery of 5-aminosalicylic acid alleviates severity of DSS-induced ulcerative colitis.

Mater Sci Eng C Mater Biol Appl 2021 Feb 6;119:111582. Epub 2020 Oct 6.

Department of Nano-Therapeutics, Institute of Nano Science and Technology, Habitat Centre, Phase 10, Sector 64, Mohali, Punjab 160062, India. Electronic address:

Ulcerative colitis (UC) is an inflammatory condition involving ulcers in colon and rectum. Conventional treatments for colitis confront serious limitations like off target systemic side effects, drug degradation and inactivation, restricted absorption and other complications culminating in poor bioavailability. These limitations necessitate localized drug delivery to inflamed colon such that drug can bypass abrasive gastric surroundings, availing protection form gastric acid and has selective access to colonic mucosa. Read More

View Article and Full-Text PDF
February 2021

Evaluation of Two Fecal Occult Blood Tests for Detecting Non-Perforating Abomasal Lesions in Cattle.

Animals (Basel) 2020 Dec 9;10(12). Epub 2020 Dec 9.

Department of Veterinary Clinical Sciences, University of Copenhagen, Højbakkegård Alle 5A, DK-2630 Taastrup, Denmark.

Non-perforating abomasal lesions occur with a high prevalence in slaughtered dairy cattle. Ante mortem diagnosis is a challenge, but the presence of occult blood in feces is suggested as a diagnostic criterion. The lower detection limit of Hemo-Fec (Med-Kjemi, Asker, Norway) and Hemoccult II SENSA (Beckman Coulter, Brea, California, USA) for fecal occult blood were estimated. Read More

View Article and Full-Text PDF
December 2020

New fecal bacterial signature for colorectal cancer screening reduces the fecal immunochemical test false-positive rate in a screening population.

PLoS One 2020 1;15(12):e0243158. Epub 2020 Dec 1.

GoodGut SL, Girona, Spain.

Guidelines recommend routine screening for colorectal cancer (CRC) in asymptomatic adults starting at age 50. The most extensively used noninvasive test for CRC screening is the fecal immunochemical test (FIT), which has an overall sensitivity for CRC of approximately 61.0%-91. Read More

View Article and Full-Text PDF
January 2021

The Clinical Utility of Faecal Calprotectin in Patients with Differentiated and Undifferentiated Spondyloarthritis: Relevance and Clinical Implications.

Reumatol Clin 2020 Nov 21. Epub 2020 Nov 21.

Faculty of Behavioural, Management and Social sciences, Department Psychology, Health and Technology, University of Twente, Enschede, The Netherlands.

Objectives: There is cumulative evidence in the literature supporting a potential role of faecal calprotectin (FCP) as a biomarker for gut inflammation in spondyloarthritis (SpA). However its relevance in undifferentiated SpA (USpA) is still uncertain. The aim of the current study is to assess the diagnostic significance of FCP levels in patients with differentiated and undifferentiated SpA. Read More

View Article and Full-Text PDF
November 2020

Occult Colonic Perforation in a Patient With Coronavirus Disease 2019 After Interleukin-6 Receptor Antagonist Therapy.

Open Forum Infect Dis 2020 Nov 12;7(11):ofaa424. Epub 2020 Sep 12.

Division of Pulmonary and Critical Care, Department of Medicine at University of California, Los Angeles, California, USA.

Background: Interleukin-6 blockade (IL-6) has become a focus of therapeutic investigation for the coronavirus disease 2019 (COVID-19).

Methods: We report a case of a 34-year-old with COVID-19 pneumonia receiving an IL-6 receptor antagonist (IL-6Ra) who developed spontaneous colonic perforation. This perforation occurred despite a benign abdominal exam and in the absence of other known risk factors associated with colonic perforation. Read More

View Article and Full-Text PDF
November 2020

Noninvasive strategies for colorectal cancer screening: opportunities and limitations.

Curr Opin Gastroenterol 2021 Jan;37(1):44-51

Division of Gastroenterology, Department of Medicine, University of Minnesota.

Purpose Of Review: In the United States, only 67% of patients are up to date with colorectal cancer (CRC) screening. While colonoscopy is highly sensitive and specific for CRC and precursor lesion detection and removal, it is invasive, expensive and resource heavy. Hence, there is an unfulfilled need for multiple modality CRC screening that can improve current CRC screening rates and may be resource effective strategies when used in conjunction with a colonoscopy program. Read More

View Article and Full-Text PDF
January 2021

Making a Decision between Acute Appendicitis and Acute Gastroenteritis.

Children (Basel) 2020 Oct 11;7(10). Epub 2020 Oct 11.

Department of Pediatrics, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 833, Taiwan.

Acute appendicitis is one of the most common pediatric abdominal emergencies. Early diagnosis is vital for a positive outcome. However, it may initially present with diarrhea and vomiting, mimicking acute gastroenteritis, thus delaying prompt surgery. Read More

View Article and Full-Text PDF
October 2020

Cost-effectiveness analysis of alternative colon cancer screening strategies in the context of the French national screening program.

Therap Adv Gastroenterol 2020 20;13:1756284820953364. Epub 2020 Sep 20.

Institut National du Cancer, Boulogne, France.

Background: A nationwide colorectal cancer (CRC) screening program was set up in France from 2009 for average-risk, asymptomatic people aged 50-74 years based on an immunochemical fecal occult blood test [faecal immunochemical test (FIT)] every 2 years, followed by colonoscopy if positive. The European standard recommends a participation rate of 45% for the program to be cost-effective, yet the latest published rate in France was 34%. The objective of this study was to compare the cost effectiveness of screening alternatives taking real-world participation rates into account. Read More

View Article and Full-Text PDF
September 2020

Faecal tests in the early detection of colorectal cancer.

Authors:
Joanna Kowalik

Prz Gastroenterol 2020 19;15(3):200-206. Epub 2020 Sep 19.

Diagnostic Laboratory of The Bonifratri Order Hospital of Saint John Grande, Krakow, Poland.

Colorectal cancer is one of the most common cancers in the world. It is the second most common cause of cancer deaths in both genders in Poland. Screening tests allow for early cancer detection, resulting in reduced mortality and better prognosis. Read More

View Article and Full-Text PDF
September 2020

A 5-year evaluation of using stool-based test for opportunistic colorectal cancer screening in primary health institutions across Malaysia.

Cancer Epidemiol 2020 12 28;69:101829. Epub 2020 Sep 28.

Department of Medicine, Sultanah Bahiyah Hospital, 05460 Alor Setar, Kedah, Malaysia. Electronic address:

Introduction: The immunochemical fecal occult blood test (iFOBT) has been widely used for opportunistic colorectal cancer (CRC) screening in average-risk individuals seeking care from public health clinics in Malaysia. This study provides a 5-year outcome evaluation of such a practice.

Methods: The findings for a few outcome indicators, ranging from the iFOBT uptake to the CRC and polyp detection rates, were generated from the data contributed by 583 public health clinics between 2014 and 2018. Read More

View Article and Full-Text PDF
December 2020

Colorectal cancer screening completion: An examination of differences by screening modality.

Prev Med Rep 2020 Dec 11;20:101202. Epub 2020 Sep 11.

Population Health Science Program, Robert D. and Patricia E. Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, United States.

Average-risk colorectal cancer (CRC) screening is broadly recommended, using one of several endorsed test options. However, CRC screening participation rates remain below national goals. To gain further insights regarding recent, population-based patterns in overall and test-specific CRC screening participation, we conducted a retrospective study of adults, ages 50-75 years, utilizing comprehensive data resources from the Rochester Epidemiology Project (REP). Read More

View Article and Full-Text PDF
December 2020

The Use of M2-Pyruvate Kinase as a Stool Biomarker for Detection of Colorectal Cancer in Tertiary Teaching Hospital: A Comparative Study.

Ann Coloproctol 2020 Dec 18;36(6):409-414. Epub 2020 Sep 18.

Department of Surgery, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Malaysia.

Purpose: Guaiac fecal occult blood test (gFOBT) has been the standard for colorectal screening but it has low sensitivity and specificity. This study evaluated the use of fecal tumor M2-pyruvate kinase (M2-PK) for detection of colorectal cancer and to compare with the current surveillance tool; gFOBT in symptomatic adult subjects underwent colonoscopy.

Methods: Stool samples were collected prospectively from symptomatic adults who had elective colonoscopy from September 2014 to January 2016 and were analyzed with the ScheBo M2-PK Quick test and laboratory detection of fecal hemoglobin. Read More

View Article and Full-Text PDF
December 2020